In the last few years, the DNA sequencing platforms have witnessed huge advancements and it’s been possible because of high-end technological developments on board.
Metagenomics Industry Overview:
In the last few years, the DNA sequencing platforms have witnessed huge advancements and it’s been possible because of high-end technological developments on board. Rising outlays for R&D activities and waning expenses of sequencing have worked as the major factors driving the metagenomics market in more than one way. At the same time, growing interest of researchers in the field of metaproteomic, meta transcriptomics, and metabolomics and increasing expenditure in bioinformatics to endorse the profile of metagenomics and microbiome have supplemented the growth yet more. Especially, the fact that innovations in the field of DNA gives way to an array of advantages compared to its traditional counterparts has become highly beneficial for the market growth.
According to Allied Market Research, the global metagenomics market is anticipated to portray a noteworthy CAGR from 2017 to 2024. Metagenomic sequencing, nowadays, allows researchers to examine an entire assortment of genomes from a miscellaneous collection of microorganisms concurrently. It not only plays an important role in interpreting animal or human microbiomes, but also has a greater role to play in detecting infections, or keeping a check on the emerging pathogens.
Request for Sample Report for More Insights@ https://www.alliedmarketresearch.com/request-sample/3724
Impact of COVID-19 Pandemic on Metagenomics Market:
Here, it’s worth stating that the emergence of Covid-19 pandemic has impacted the global metagenomics market positively. mNGS has now turned out to be one of the most effective techniques in identifying SARS-CoV-2 from NP swabs along with laying out information on the structure of the microbiome in the upper respirational zone and aids in examining its connection to the presence of other organisms that may influence the very progression of SARS-CoV-2 disease. This, in turn, has escalated the demand for metagenomics sequencing in the healthcare sector, and this drift is also most likely to continue till the pandemic is completely over. In a nutshell, it can be concluded that the global market for metagenomics does have solid growth prospects in the years to come.
Metagenomics seems highly poised to make the significant leap from the laboratory pew to the clinic. Back in the year 2014, the first case report validated successful use of metagenomics for identification and treatment of a patient who was critically ill. Charles Y. Chiu, a renowned professor of laboratory medicine at the University of California, directed a scientific unit that identified neuroleptospirosis in a cerebrospinal fluid trial through sequencing, after a traditional infectious disease diagnosis revealed no desired result. The patient was then given proper antibiotic treatment, which led to his recovery gradually.
Top Leading Players:
- Agilent Technologies, Inc
- Enterome SA
- Illumina Inc.
- Oxford Nanopore Technologies Ltd.
- Pacific Biosciences of California Inc.
- PerkinElmer Inc.
- QIAGEN N.V.
- Swift Biosciences Inc.
- Thermo Fisher Scientific Inc.